

Clem W Imrie

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2965054/clem-w-imrie-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

25
papers

3,351
citations

19
h-index

30
g-index

30
ext. papers

3,774
ext. citations

5.6
avg, IF

4.34
L-index

#	Paper	IF	Citations
25	Host systemic inflammatory response influences outcome in pancreatic cancer. <i>Pancreatology</i> , 2015, 15, 327-30	3.8	16
24	When to perform a pancreateoduodenectomy in the absence of positive histology? A consensus statement by the International Study Group of Pancreatic Surgery. <i>Surgery</i> , 2014, 155, 887-92	3.6	89
23	Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). <i>Surgery</i> , 2014, 155, 977-88	3.6	554
22	Extended pancreatectomy in pancreatic ductal adenocarcinoma: definition and consensus of the International Study Group for Pancreatic Surgery (ISGPS). <i>Surgery</i> , 2014, 156, 1-14	3.6	154
21	The relationship between tumor inflammatory cell infiltrate and outcome in patients with pancreatic ductal adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2012, 19, 3581-90	3.1	47
20	Etiology, pathogenesis, and diagnostic assessment of acute pancreatitis 2012, 836-844.e3		
19	The Challenges of Improving Survival Following Pancreateoduodenectomy for Pancreatic Ductal Adenocarcinoma. <i>Annals of Surgery</i> , 2011, 254, 386	7.8	
18	A prospective comparison of the prognostic value of tumor- and patient-related factors in patients undergoing potentially curative surgery for pancreatic ductal adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2011, 18, 2318-28	3.1	96
17	Peripancreatic fat invasion is an independent predictor of poor outcome following pancreateoduodenectomy for pancreatic ductal adenocarcinoma. <i>Journal of Gastrointestinal Surgery</i> , 2011, 15, 512-24	3.3	20
16	Positive mobilization margins alone do not influence survival following pancreatico-duodenectomy for pancreatic ductal adenocarcinoma. <i>Annals of Surgery</i> , 2010, 251, 1003-10	7.8	153
15	Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. <i>Pancreatology</i> , 2006, 6, 450-3	3.8	134
14	Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas. <i>British Journal of Cancer</i> , 2005, 92, 21-3	8.7	128
13	Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography. <i>Gastroenterology</i> , 2003, 124, 1786-91	13.3	215
12	Dynamic nature of early organ dysfunction determines outcome in acute pancreatitis. <i>British Journal of Surgery</i> , 2002, 89, 298-302	5.3	392
11	Enteral and parenteral nutrition in acute pancreatitis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2002, 16, 391-7	2.5	21
10	Double blind, randomised, placebo controlled study of a platelet activating factor antagonist, lexipafant, in the treatment and prevention of organ failure in predicted severe acute pancreatitis. <i>Gut</i> , 2001, 48, 62-9	19.2	236
9	Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. <i>Annals of Surgery</i> , 2001, 234, 758-68	7.8	482

LIST OF PUBLICATIONS

8	Percutaneous necrosectomy and sinus tract endoscopy in the management of infected pancreatic necrosis: an initial experience. <i>Annals of Surgery</i> , 2000 , 232, 175-80	7.8	279
7	High early mortality rate from acute pancreatitis in Scotland, 1984-1995. <i>British Journal of Surgery</i> , 1999 , 86, 1302-5	5.3	205
6	The possible role of platelet-activating factor antagonist therapy in the management of severe acute pancreatitis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 1999 , 13, 357-64	2.5	12
5	Staging of acute pancreatitis. Is it important?. <i>Surgical Clinics of North America</i> , 1999 , 79, 733-43	4	35
4	The scientific basis of medical therapy of acute pancreatitis. Could it work, and is there a role for lexipafant?. <i>Gastroenterology Clinics of North America</i> , 1999 , 28, 591-9, ix	4.4	7
3	A randomized, controlled trial of octreotide in the management of patients with acute pancreatitis. <i>International Journal of Gastrointestinal Cancer</i> , 1997 , 21, 13-9		40
2	The Hong Kong criteria and severity prediction in acute pancreatitis. <i>International Journal of Gastrointestinal Cancer</i> , 1994 , 15, 179-85		11
1	Somatostatin and somatostatin analogues--are they indicated in the management of acute pancreatitis?. <i>Gut</i> , 1993 , 34, 1622-6	19.2	21